Oncology and Hematology - Global Oncology Academy

Episodes 225-240 of 390

Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Project Oncology®
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
- Alan Bryce, MD
Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms
Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms
DermConsult
Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
Project Oncology®
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
- Charles Turck, PharmD, BCPS, BCCCP
- Neeraj Agarwal, MD, FASCO
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
Project Oncology®
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
- Rishi Sekar, MD
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Project Oncology®
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
- Zachery Reichert MD, PhD
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Global Oncology Academy
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
- Jacob Sands, MD
- Aakesh Desai, MD, MPH
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
MinuteCE®
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
MinuteCE®
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
MinuteCE®
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
MinuteCE®
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
MinuteCE®
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
MinuteCE®
Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies
1.25 credits 11 episodes
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 credits 11 episodes

15/11